LYON, France, September 22, 2022 -- EDAP TMS S.A. (NASDAQ: EDAP) (the “Company”), a global leader in robotic energy-based therapies, announced today that it has commenced a public offering of its American Depositary Shares, or ADSs, each representing one ordinary share of the Company.

Announced Focal One® HIFU reimbursement raised to urology APC Level 6 under CMS Outpatient Prospective Payment System (OPPS) proposed rule for CY23 Second quarter 2022 total revenue of approximately EUR 14.2 million (USD 15.0 million), an increase of 36.7% as compared to EUR 10.4 million (USD 12.4

Company to host conference call and webcast on Thursday , August 25 th at 8:30 am EDT LYON, France, August 3 , 20 2 2 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the second quarter ended June 30 th

Proposed rule, if adopted for CY23 , would increase Medicare Payment for a Focal One HIFU procedure completed on an outpatient basis at a hospital LYON, France, July 18, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that the

  LYON, France, June 28, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced its participation to two major forthcoming international robotics and urology congresses: EAU : European Association of Urology – Amsterdam July 1-4

LYON, France, June 14, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Prof. Gil Dubernard, Head of the Gynecology Department at Croix-Rousse University Hospital, Lyon, France, will deliver a presentation at the 6 th

LYON, France, June 6, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that three oral presentations will be delivered on its HIFU developments at the 21 st Annual International Symposium on Therapeutic Ultrasound (ISTU), which

First quarter 2022 revenue of approximately EUR 13.0 million (USD 14.5 million), an increase of 26% as compared to EUR 10.3 million (USD 12.4 million) for the first quarter 2021 Four Focal One units sold in Q1 2022 versus zero in Q1 2021 Strong cash position of $51.6 million as of March 31, 2022

Company to host conference call and webcast on , Wednesday, May 18 th at 8:30 am EDT LYON, France, May 10, 20 2 2 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the first quarter ended March 31 st ,

  AUA is the largest annual gathering of urologists worldwide LYON, France, May 5, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that the company will be showcasing and exhibiting its Focal One® Robotic High Intensity